Navigation Links
Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008

WALTHAM, Mass., Aug. 8 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of near-patient diagnostics, monitoring and health management solutions, is featuring its new TB diagnostic test, the Clearview TB ELISA, at the International AIDS conference (AIDS 2008).

The test, which was introduced to developing world markets in July 2008, provides a much needed aid in the diagnosis of Mycobacterium tuberculosis (TB) in TB/HIV co-infected patients. By providing reliable information more quickly, when compared to other methods, the Clearview TB ELISA can enable treatment decisions to be made the very same day, allowing for more effective patient health management and mitigating the risk of further transmission to a highly vulnerable population.

The Clearview TB ELISA has shown strong performance in detecting TB in those co-infected with HIV. Clearview TB ELISA uses antibodies specific to the antigen lipoarabinomannan (LAM). Elevated levels of the LAM antigen within the urine of TB/HIV co-infected patients provides a specific and reliable diagnostic target. Clinical data shows that, while microscopy methods detect TB in these TB/HIV co-infected patients, at rates as low as 20%, targeting the LAM antigen using the Clearview TB ELISA can produce detection rates of 80%.

Ron Zwanziger, Inverness' CEO stated, "Introduction of the Clearview TB ELISA is an important first step in making available much-needed diagnostic tools to address the TB epidemic where the need is greatest. We are working hard to build support for its widespread adoption."

There were approximately 33 million people living with HIV infection in 2007 and due to their compromised immune status, more than one third were co-infected with TB. As a result, TB has become a leading cause of death in this population and there is a dire need for reliable TB diagnostics.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

For more information about Inverness Medical Innovations, please visit our website at

This press release may contain forward-looking statements within the meaning of the federal securities laws, including statements regarding timing of the product release and benefits of the new product. These statements reflect Inverness' current views with respect to future events and are based on its management's current assumptions and information currently available. Actual results may differ materially due to numerous factors including, without limitation, risks associated with market acceptance of the product; Inverness' ability to successfully manufacture and distribute the product; Inverness ability to secure and maintain the regulatory approvals or clearances necessary to sell the product in various markets; and the risks and uncertainties described in Inverness' annual report on Form 10-K, and other factors identified from time to time in its periodic filings with the Securities and Exchange Commission. Inverness undertakes no obligation to update any forward-looking statements contained herein.

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
2. Inverness Medical Innovations Announces Second Quarter 2008 Results
3. Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008
4. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
5. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
6. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
7. Inverness Medical Innovations to Participate at Morgan Stanley Global Healthcare Unplugged Conference on April 30, 2008
8. Inverness Medical Innovations Announces First Quarter 2008 Results
9. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
10. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
11. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
Post Your Comments:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):